Powerful Clinical Performance in International Patient Population

Demonstrated Safety & Efficacy

Demonstrated Safety & Efficacy


  • 240 patients with clinical follow-up
  • 153 patients with OCT follow-up
  • 28 centers
  • 8 countries

12-month Clinical Results presented at EuroPCR 2017

Interim 24-month Clinical Results presented at TCT 2017

Excellent Vessel Healing & Scaffold Coverage

In FANTOM II, REVA generated one of the largest OCT data sets for BRS. Results from the OCT study have demonstrated that the vessel lumen is maintained at 6 and 9 months follow up with minimal malapposition and excellent strut coverage. See our Education Center for OCT images from the study.

Vessel Patency Maintained2

Mean Scaffold Area Baseline Follow up
Cohort A – 6 Month Follow up (n=73) 7.1mm2 7.2mm2
Cohort B – 9 Month Follow up (n=80) 7.4mm2 7.3mm2

Malapposition Resolved2

 Malapposition Baseline Follow up
Cohort A – 6 Month Follow up (n=73) 0.8% 0.0%
Cohort B – 9 Month Follow up (n=80) 1.6% 0%

Strut Coverage

Strut Coverage Follow up
Cohort A – 6 Month Follow up (n=73) 98.1%
Cohort B – 9 Month Follow up (n=80) 99.0%

FANTOM Global Clinical Program

REVA Medical is committed to advancing the field of BRS. The FANTOM Clinical Program is designed to evaluate performance in a variety of patient and lesion types.

FANTOM Global Clinical program


  1. Hermiller, J. Fantom: A Radio-Opaque “Stent-Like” BRS with Improved Expansion Characteristics. Presented TCT 2017. MACE = Cardiac Death + All MI + Clinically Driven TLR.; 24-month data is interim data set, n=125.
  2. Holm, N. REVA Fantom II performance and healing patterns by OCT. REVA Symposium EuroPCR 2017.